Diabetes Australia welcomes the Federal Authorities’s resolution to ban replicas of Ozempic and different weight reduction drugs following security considerations.
Pharmacies compounding their very own variations of those drugs have been ordered to cease manufacturing from October 1, 2024.
The brand new laws will take away glucagon-like peptide-1 receptor agonists (GLP-1RAs), a lot of which declare to be replicas of Ozempic or Mounjaro, from the pharmacy compounding exemption.
Diabetes Australia understands the numerous considerations of Australians residing with sort 2 diabetes concerning the ongoing world scarcity of Ozempic specifically, and can proceed to advocate for prioritised entry for individuals residing with diabetes.
Nonetheless, with regards to compounded variations, the well being and wellbeing of the neighborhood should be a very powerful consideration.
The compounded GLP-1RA merchandise the federal government has banned haven’t been evaluated by the TGA for security, high quality and efficacy. When a drugs is compounded, it will probably have a unique power and totally different substances from comparable medicines permitted by the TGA.
Diabetes Australia has advocated for the Therapeutic Items Administration (TGA) to research the shortages of quite a few diabetes-related medicines and merchandise in recent times and redouble efforts to make sure Australians might be assured that provide chains are adequate to satisfy their wants.
Extra details about the protection of those merchandise might be discovered on the TGA web site.
